Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

doi:10.1200/JCO.2009.27.4860

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Nov 2010

Douillard Jean-Yves, Siena Salvatore, Cassidy James, Tabernero Josep, Burkes Ronald, Barugel Mario, Humblet Yves, Bodoky György, Cunningham David, Jassem Jacek, Rivera Fernando, Kocákova Ilona, Ruff Paul, Błasińska-Morawiec Maria, Šmakal Martin, Canon Jean-Luc, Rother Mark, Oliner Kelly S, Wolf Michael, Gansert Jennifer

Abstract excerpt

PURPOSE: Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as monotherapy for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) was designed to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Administration Schedule

Share to Fluorouracil

Share to Infusions, Intravenous

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Panitumumab

Source

Open in PubMed

Identifiers

PMID: 20921465
DOI: 10.1200/JCO.2009.27.4860

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.PMID 20921465Read ↗

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.Semantic proximity Read ↗

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.Semantic proximity Read ↗

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.Semantic proximity Read ↗

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.Semantic proximity Read ↗

Integration of panitumumab into the treatment of colorectal cancer.Semantic proximity Read ↗

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).Semantic proximity Read ↗

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.Semantic proximity Read ↗

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.